89bio rises after $250 mln equity haul
Akero Therapeutics gains after upsized $350 mln equity raise
Brief: 89Bio Announces Pricing Of $250 Mln Public Offering Of Common Stock And Pre-Funded Warrants
89bio slides on stock offering to fund MASH drug
Brief: 89Bio Provides Business Update And Outlook For 2025
Brief: 89Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Charter Communications, BioNTech, Big US banks
U.S. STOCKS ON THE MOVE-BankUnited, Natera, Adaptimmune
U.S. STOCKS ON THE MOVE-Rivian, Amgen, Cava
89bio slips after $125 mln stock deal
Brief: 89Bio, Inc. Announces Upsized Pricing Of $125.0 Million Public Offering Of Common Stock And Pre-Funded Warrants
89Bio Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: 89bio Q3 Net Income USD -149.073 Million Vs. IBES Estimate USD -65 Million
89Bio Inc expected to post a loss of 64 cents a share - Earnings Preview
Brief: 89Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
89Bio Inc reports results for the quarter ended in June - Earnings Summary
U.S. RESEARCH ROUNDUP- Actinium Pharmaceuticals, Albemarle, ArcBest
Brief: 89bio Q2 Net Income USD -47.971 Million Vs. IBES Estimate USD -56.1 Million
89Bio Inc expected to post a loss of 57 cents a share - Earnings Preview